David Stanton, MD
Gastroenterology · Orange, CANPI 1821101163
Payments from drug & device makers
Across 60 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$253
- Johnson & Johnson$150
- Madrigal Pharmaceuticals$116
- Sanofi$100
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$96
- Takeda Pharmaceuticals U.S.A., Inc.$89
- plus $448 from 11 others
What the payments were for
- Food & beverage$1,22097%
- Education$313%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 12 | $253 |
| Johnson & Johnson | 7 | $150 |
| Madrigal Pharmaceuticals | 4 | $116 |
| Sanofi | 4 | $100 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $89 |
| Phathom Pharmaceuticals, Inc. | 5 | $88 |
| Ardelyx, Inc. | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 2 | $51 |
| Celltrion USA Inc. | 3 | $49 |
| AbbVie | 2 | $31 |
| QOL Medical, LLC | 1 | $31 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Shionogi Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
| Intercept Pharmaceuticals, Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
How this compares
$1,252 in reported general payments places this provider in the 40th percentile of 1,885 gastroenterology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nalbuphine Hcl | 11 | $10,182 |
| Insulin SyringeSyringe And Needle,insulin,1ml | 13 | $1,028 |
| Sucralfate | 13 | $480 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 16 | $466 |
| LoperamideLoperamide Hcl | 12 | $351 |
| Omeprazole | 14 | $213 |
| Amitriptyline Hcl | 11 | $197 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 12 | $71 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Orange
- Alaa AbousaifOrange$1.8M
- Peter WinkleCypress$116.7M
- Manuchehr DaraniSanta Ana$17.7M
- Jatinder PruthiLancaster$4.4M
- Long DangWestminster$4.3M
- Muhammad SheikhFresno$4.3M
- Gregory WienerChula Vista$3.5M
- Gil MelmedLos Angeles$3M
- Christopher BowlusSacramento$3M
- Bennett RothLos Angeles$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.